Research
Lp(a)-Lowering Pelacarsen Shows Huge Disconnect With Cardiovascular Outcomes
The Brief
- In the Lp(a) HORIZON trial, lowering lipoprotein(a) with pelacarsen did not translate into better cardiovascular outcomes.
- The result applies to a secondary prevention population with elevated lipoprotein(a).
- The source describes a large disconnect between Lp(a) lowering and cardiovascular outcomes.
Why it matters
Lowering Lp(a) alone did not reduce cardiovascular events in this trial, so Lp(a) reduction may not be enough to improve outcomes for patients already treated for cardiovascular disease.
Who’s affected
- People with elevated lipoprotein(a) in secondary prevention
- #lipoprotein(a)
- #pelacarsen
- #cardiovascular outcomes
- #clinical trial
- #secondary prevention
(MedPage Today) -- Lowering lipoprotein(a), or Lp(a), did not translate into better cardiovascular outcomes in a secondary prevention population, at least not with pelacarsen in the Lp(a) HORIZON trial. Among people with elevated lipoprotein(a...